Nanomath LLC

Nanomath LLC

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Nanomath LLC is a private, US-based company founded in 2018, focusing on AI/ML and drug delivery through advanced modeling and simulation. Its core business revolves around providing PK-PD, PBPK, and QSP services and distributing the legacy SAAM II software, a foundational tool for compartmental modeling. The company appears to be in an early-revenue stage, leveraging its academic connections and niche software expertise to serve clients in long-acting product development. Its model is service-oriented, positioning it as a specialized technical partner rather than a therapeutic developer.

AI / Machine LearningDrug Delivery

Technology Platform

Specializes in PK-PD, PBPK, and QSP modeling and simulation services. Official distributor of SAAM II software for compartmental modeling. Developer of Automated Oral minimal Models (AOMM™) platform.

Opportunities

The growing adoption of model-informed drug development (MIDD) by regulators and pharma creates strong demand for specialized PK/PD services.
The increasing focus on complex long-acting drug delivery systems represents a specific, high-value niche where Nanomath's expertise is directly applicable.

Risk Factors

Reliance on the legacy SAAM II software distribution and consulting services creates vulnerability to competition from modern, open-source modeling platforms.
As a small service provider, the company is highly sensitive to fluctuations in pharmaceutical R&D budgets and client concentration.

Competitive Landscape

Nanomath competes with large CROs (e.g., Certara, which has its own respected software like Phoenix) that offer full-service modeling and simulation, as well as with specialized consulting firms and academic groups. Its unique position as the SAAM II distributor gives it a defensible niche but within a limited market.